Statements
What is already known about this subject.
- Capmatinib is an orally bioavailable, highly potent and selective MET
inhibitor with recent approval to treat adult patients with metastatic
NSCLC with METex14 skipping mutations.
- The pharmacokinetics of oral capmatinib has been characterized in
multiple clinical trials previously.
- In vitro studies showed that capmatinib inhibits transporter -gp and
BCRP.
What this study adds.
- Capmatinib inhibits P-gp and BCRP at a clinically relevant therapeutic
dose.
- The results of this study will inform the safe use of P-gp and BCRP
substrates when coadministration of capmatinib is required.